CLASS II Drug recall · Reported 29 Jun 2022 · FDA Enforcement Report

Testosterone Cypionate Injection recalled

Sun Pharmaceutical Industries is recalling Testosterone Cypionate Injection, USP, 200 mg/mL Single-dose vial per, distributed nationwide in the US. The recall was initiated on 3 Jun 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesHAC1974A, HAC1978A, Exp 06/2023
NDC62756-015, 62756-017, 62756-016
UPC0362756017405, 0362756015401, 0362756016408
Quantity recalled97,450 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1153-2022
FDA event ID
90361
Recalling firm
Sun Pharmaceutical Industries, Princeton, NJ
Manufacturer
Sun Pharmaceutical Industries, Inc.
Classification
Class II
Status
Terminated
Recall initiated
3 Jun 2022
FDA classified
21 Jun 2022
Reported
29 Jun 2022
Type
Voluntary: Firm initiated
Reason category
Potency & Assay

Timeline

3 Jun 2022Recall initiated by company
21 Jun 2022Classified by FDA+18 days
29 Jun 2022Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: lots made with same active pharmaceutical ingredient (API) as lots that were rejected due to manufacturing issues that could cause the product to be out of specification for impurities.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Testosterone Cypionate Injection, USP, 200 mg/mL, 1 mL Single-dose vial per carton, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Industries Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 62756-015-40.

Where it was distributed

Nationwide in the USA and Puerto Rico

Nationwide Puerto Rico

Questions about this recall

Is Testosterone Cypionate Injection, USP, 200 mg/mL Single-dose vial per recalled?

Yes. Sun Pharmaceutical Industries recalled Testosterone Cypionate Injection, USP, 200 mg/mL Single-dose vial per on 3 Jun 2022. The recall is Class II and its status is Terminated. Recall number D-1153-2022.

Why was it recalled?

CGMP Deviations: lots made with same active pharmaceutical ingredient (API) as lots that were rejected due to manufacturing issues that could cause the product to be out of specification for impurities.

Which lots are affected?

HAC1974A, HAC1978A, Exp 06/2023

Where was it sold?

Nationwide in the USA and Puerto Rico

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Sun Pharmaceutical Industries

All 138

Other Testosterone Cypionate recalls

All 23